Key Dates

Related Announcements

PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

PA-19-271 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

PA-19-273 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

PA-19-272 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Issued by

National Institute on Deafness and Other Communication Disorders (NIDCD)

Purpose

Coronavirus Disease 2019 (COVID-19) is a recently emerged human disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is a paucity of data on the impact of SARS-CoV-2 on the sensory and communicative functions within the scientific mission areas of NIDCD. NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

Research

Areas of COVID-19 related research encouraged through this Notice include, but are not limited to studies on or related to:

• The effects of prolonged oral intubation on laryngeal function and voice production
• Short-term and long-term effects of COVID-19 on the auditory, vestibular or olfactory systems
• The prevalence, onset, and resolution of acquired deficits (i.e. HBTSVSL) among patients with COVID-19 across the lifespan and in association with various underlying genetic predispositions and health conditions
• The molecular mechanisms underlying chemosensory dysfunction due to SARS-CoV-2 infection
• The impact of stress/isolation on speech, language or fluency recovery/development in children or adults
• The impact of potential congenital transmission of maternal SARS-CoV-2 infection to the newborn in relation to the auditory, vestibular, olfactory, or vocal function and/or the impact on speech production or language acquisition
• Potential ototoxicity from therapeutics or vaccination related to COVID-19
• Worsening of communicative function because of physical distancing, sheltering in place, and wearing of protective personal equipment during mitigation of this infectious pandemic
• Telehealth service delivery to individuals with communication disorders
• Multidisciplinary collaborative teams including clinicians, basic biologists, geneticists, quantitative scientist, epidemiologists or other researchers to study COVID-19 related human conditions and behaviors, bioethical considerations, health-service delivery, health services in low-resource areas, and health disparities within NIDCD mission areas

Application and Submission Information

This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

Applicants responding to this NOSI are strongly encouraged to consider utilizing existing disaster research tools and COVID-19 surveys, if appropriate, which are available at https://dr2.nlm.nih.gov. Additionally, researchers funded under this NOSI who develop novel survey instruments, will be required to share these item by depositing them into [email protected]

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

• PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
• PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

• PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

• PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

• PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

The initial Small Business due dates must use the reissue of the following Parent Announcements to ensure correct forms package (i.e. FORMS-F).

• PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

• PA-19-271 - PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

• PA-19-273 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

• PA-19-272 - PHS 2019-02 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include “NOT-DC-20-008" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in Box 4B will not be considered for this initiati

Inquiries

Scientific/Research Contact(s)

Bracie Watson, Jr. Ph.D.

NIDCD/Division of Scientific Programs

Telephone: 301-402-3458

Email: [email protected]

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Christopher Myers

NIDCD/Grants Management

Telephone: 301-435-0713

Email: [email protected]